To explore the roles of CEA glycosylation in cancer patients, we investigated their performance in 16 advanced CRC and seven advanced lung cancer patients with CEA overexpressed (>300 ng/ml, Supplemental Table S1), whose age and sex were almost the same (Fig. 5A). Here, CEACAM5 is linked to cancer.